Helix BioPharma (TSE:HBP) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Helix BioPharma Corp. showcased its innovative L-DOS47 platform at the World ADC San Diego, underscoring its potential in treating hard-to-treat cancers by enhancing the immune system’s response. The company is advancing towards a Phase II study for non-small cell lung cancer and exploring broader applications across various cancer types.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
